Sit Investment Associates Inc. raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 21.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 29,125 shares of the medical device company’s stock after buying an additional 5,225 shares during the period. Sit Investment Associates Inc.’s holdings in DexCom were worth $2,130,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Morgan Stanley raised its position in shares of DexCom by 18.0% in the first quarter. Morgan Stanley now owns 2,092,962 shares of the medical device company’s stock worth $177,336,000 after buying an additional 319,631 shares during the last quarter. DUPONT CAPITAL MANAGEMENT Corp acquired a new stake in DexCom during the first quarter worth $270,000. Swiss National Bank raised its stake in DexCom by 28.4% in the first quarter. Swiss National Bank now owns 299,500 shares of the medical device company’s stock worth $25,377,000 after buying an additional 66,200 shares during the last quarter. Credit Suisse AG raised its stake in DexCom by 0.3% in the first quarter. Credit Suisse AG now owns 302,130 shares of the medical device company’s stock worth $25,599,000 after buying an additional 791 shares during the last quarter. Finally, Teachers Advisors LLC increased its stake in shares of DexCom by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 184,560 shares of the medical device company’s stock worth $11,018,000 after buying an additional 7,050 shares during the period.
DexCom, Inc. (NASDAQ:DXCM) traded up 2.58% during midday trading on Wednesday, hitting $73.06. 752,124 shares of the company traded hands. The stock’s market cap is $6.32 billion. The stock has a 50 day moving average of $70.72 and a 200 day moving average of $74.97. DexCom, Inc. has a 12-month low of $57.68 and a 12-month high of $96.38.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.07. The company had revenue of $170.60 million during the quarter, compared to analysts’ expectations of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. DexCom’s revenue for the quarter was up 24.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.24) earnings per share. Equities research analysts predict that DexCom, Inc. will post ($0.77) EPS for the current fiscal year.
WARNING: “DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Sit Investment Associates Inc.” was reported by BBNS and is the property of of BBNS. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/dexcom-inc-nasdaqdxcm-stake-raised-by-sit-investment-associates-inc-updated-updated-updated/1253877.html.
DXCM has been the subject of a number of recent research reports. Jefferies Group LLC cut their price objective on shares of DexCom to $91.00 and set a “buy” rating for the company in a research report on Tuesday, May 9th. BMO Capital Markets restated an “outperform” rating and set a $90.00 price objective (down from $105.00) on shares of DexCom in a research report on Tuesday, August 8th. Canaccord Genuity reiterated a “buy” rating and set a $90.00 price target on shares of DexCom in a research report on Wednesday, June 7th. Zacks Investment Research upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Finally, BidaskClub lowered shares of DexCom from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the company’s stock. DexCom has a consensus rating of “Buy” and an average target price of $87.00.
In other news, EVP Richard Doubleday sold 3,182 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $68.29, for a total transaction of $217,298.78. Following the transaction, the executive vice president now owns 72,395 shares in the company, valued at $4,943,854.55. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Andrew K. Balo sold 3,200 shares of the stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $69.06, for a total value of $220,992.00. The disclosure for this sale can be found here. Insiders have sold 33,726 shares of company stock valued at $2,376,466 over the last three months. Insiders own 1.70% of the company’s stock.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with our FREE daily email newsletter.